At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 87 target
Drug / intervention
BPI-452080drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-452080 in Subjects With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating BPI-452080 for Solid Tumor and 2 related conditions. Targeting 87 participants across 5 sites.
Detailed Summary
This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202420252026
Enrollment StartApr 2023
First PostedMay 2023
Primary CompletionMar 2025
Study CompletionOct 2025
TodayJul 2026
First PostedMay 6, 2023
Enrollment StartApr 28, 2023
Primary CompletionMar 25, 2025
Study CompletionOct 31, 2025
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 3.2 years ago
Interventions
BPI-452080drug
Subjects will receive BPI-452080 until disease progression